In a further study evaluating CXCL13 mRNA expression in the FinHER trial, CXCL13 as a marker of the humoral immune system was associated with favorable prognosis, particularly in triple-negative breast cancer (TNBC) [11]. The gene discussed is CXCL13; the disease is triple-negative breast carcinoma.